Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Risperdal "Dear Doctor" Letter Minimizes Diabetes Risk, FDA Ad Division Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency warning letter says J&J inappropriately claimed that Risperdal is safer than other atypical antipsychotics. The company is working with FDA to address the agency's concerns as quickly as possible.

You may also be interested in...



J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award

A jury finds that J&J misrepresented the safety profile of Risperdal in a verdict for the state of Louisiana; each letter and sales rep call was counted as a separate violation.

J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award

A jury finds that J&J misrepresented the safety profile of Risperdal in a verdict for the state of Louisiana; each letter and sales rep call was counted as a separate violation.

Janssen Corrects Risperdal "Dear Doctor" Letter

The action follows an FDA warning letter in April. Janssen's previous letter to doctors had suggested Risperdal was safer than other atypical antipsychotics.

Related Content

Topics

UsernamePublicRestriction

Register

PS059244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel